Boosting immune response to fight cancer
Official title: Human CD3epsilon co-potentiation to boost immunotherapy
Funded at University of Missouri-Columbia · NIH-9868156 · Data updated 2026-11-12
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project start | September 20, 2019 |
| Project end | August 31, 2025 |
| Funding year | 2019 |
| Award (this year) | $3,730,200 |
| NIH project number | 1U01CA244314-01 |
| Project ID | NIH-9868156 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who have been diagnosed with metastatic cancers.
✕Less likely to help
Patients with early-stage cancers or those who do not have metastatic disease may not benefit from this research.
What this research studies
This research investigates a new method to enhance the immune system's ability to recognize and attack cancer cells by manipulating T cell receptors. The approach uses specialized fragments that target the CD3 complex on T cells, making them more responsive to cancer antigens. By combining these fragments with existing immunotherapies, the goal is to improve treatment outcomes for patients with metastatic cancers. The research has shown promising results in animal models, indicating potential effectiveness in humans.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with metastatic cancers.
How similar studies have gone: Previous research has shown success with similar immunotherapy approaches, indicating a strong potential for this method.
Where this research is happening
-
University of Missouri-Columbia
Columbia, United States Active
Researchers
- Principal investigator: Gil Pages, Diana — University of Missouri-Columbia
- Study coordinator: Gil Pages, Diana
Related research
Other NIH-funded projects on the same topics.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
-
Overcoming obesity-related resistance to immunotherapy in kidney cancer
A study aims to understand why obesity affects how well immunotherapy works for people with advanced kidney cancer and how to improve treatments for those patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.